StreetInsider
Log in to your account:
Log in
Signup
Home
EPS Insider
Event Calendar
Conferences
Classic Site
Upgrade to SI Premium - Free Trial
Seattle Genetics (SGEN) Reports Supplemental Biologics License Application Submission for ADCETRIS (Brentuximab Vedotin)
November 5, 2018 8:05 AM
Seattle Genetics, Inc. (NASDAQ: SGEN) announced today that it has submitted a supplemental Biologics License Application (BLA) to the U.S ...
(Premium-only article. Please sign in or upgrade to SI Premium to view.)
Categories
FDA
Management Comments
Next Articles
Seattle Genetics Submits Supplemental Biologics License Application for ADCETRIS® (Brentuximab Vedotin) in Frontline Treatment of CD30-Expressing Peripheral T-Cell Lymphomas
November 5, 2018 8:00 AM